24 Sep 10
In a climate of fiscal hardship, everybody has a special case to plead. Indeed, when the funding scalpel is out, every department and almost every recipient of public sector funds has a special tale to tell. The truth is, science funding really is that important.
20 Sep 10
If you have written material for a journal like this one, or a book, we may be holding monies due to you.
16 Sep 10
As healthcare innovation produces new treatments, and new information delivers increased awareness, a substantial rise in prescription drug use is only to be expected. For the most part, this can largely be seen as a positive development.
06 Sep 10
Last week, leaders from companies like AstraZeneca, GlaxoSmithKline, Pfizer and Roche met in Vienna in a closed meeting to discuss the future of the pharma industry. Fears of layoffs at pharmaceutical companies are once again dominating the news, but could there be a less painful way to save money?
02 Sep 10
Even in the good years, mental health budgets were seldom in line with what experts expected or deemed necessary. Thus, in times of budget deficits and scathing public expenditure cuts, the worry becomes even greater. For those that care most about the health service then, the Coalition government's decision to ring fence healthcare spending has been largely applauded.
25 Aug 10
Originally born under the Conservatives, but fully evolved under Labour, Private Finance Initiatives (PFIs) essentially offered the NHS an alternative way of paying for new hospitals and renovations at a time when public capital was said to be limited.
23 Aug 10
While long prohibited under UK ABPI regulations, if youâ€™ve worked in the world of big pharma in the U.S., youâ€™ll have seen it all a hundred times. A drugs company sponsors a medical conference, they pay for the meals and flights of the delegates and they hand them all a goodie bag as they leave.
12 Aug 10
Cancer Research Technology has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.
Cancer Research UK
23 Jul 10
If the nationâ€™s recruiters received a pound for every time theyâ€™d interviewed a candidate that looked good on paper but disappointed in practice, thereâ€™d currently be an awful lot of recruiters in the process of relocating to the Caribbean.
Max Golby / Mike Wood
20 Jul 10
Skin cancers come in various forms but the type which causes most fear is the malignant melanoma, derived from the pigment-forming cells of the skin or melanocytes.
Dr Laurence Lever
19 Jul 10
During a time of major economic downturn, there are few industries that can be said to be truly â€˜recession proofâ€™. Yet for years now, big pharma has largely been seen as precisely that. After all, no matter dire the markets, and no matter how low consumer confidence plummets, there is always a demand for healthcare.
25 Jun 10
In areas such as competition policy and choice in the NHS, there could be said to be much correlation between the approaches of both governments past and present. Yet in other key areas of policy, there are unquestionably examples of ideological, or at least philosophical, differences in outlook. Or at least in theory.
18 Jun 10
A selective memory is a wonderful thing. That is, if you're a conspiracy theorist or an opportunistic critic of any kind. Yet, for those of us with memories of a more consistent mold, a lot of the current and decidedly harsh criticism directed against the World Health Organizationâ€™s handling of the just passed H1N1 'Swine Flu' outbreak must be questioned in kind.
17 Jun 10
As the new Conservative-led coalition finally begins to settle down to the task ahead, questions of policy detail are increasingly replacing the brouhaha of election-time buccaneering and healthcare policy and the NHS are no exceptions to the rule â€“ particularly in the case of competition policy.
28 May 10
With every challenge comes a new opportunity. Indeed, if we are to believe the results of a recent international workforce survey by Kelly Services, while the global economic recession has produced troubles a plenty, it has also evoked a new found sense of entrepreneurialism as workers look to adjust to changing employment models and to respond to new challenges in a very human way.
28 May 10
Just five years after its formation through the merger of Fujisawa and Yamanouchi, Astellas has become one of the top 20 pharmaceutical companies in the world. Employing 15,000 people and with annual sales reaching â‚¬1,287 million in Europe, Astellas has exceeded all expectations for growth in the past five years and the companyâ€™s management team has devised a clear vision to ensure that this success continues in the years to come.
20 May 10
Economic uncertainty has fueled a growing trend toward self-employment and entrepreneurialism with one-in-five respondents worldwide now working outside the traditional employment relationship, and 50 percent saying that they would like to do so, according to the latest survey results from workforce solutions leader Kelly ServicesÂ®.
23 Apr 10
The theme for National Stop Snoring Week 2010 is all about our houses. From house dust mites to pet dogs it seems that our houses are minefields when it comes to snoring. Nobody is safe as there are dangers lurking in every room.
Marianne Davey - The British Snoring & Sleep Apnoea Association (BSSAA)
22 Apr 10
Karolinska Institutet is one of the worldÂ´s leading medical universities. Its mission is to contribute to the improvement of human health through research and education. Karolinska Institutet accounts for over 40 per cent of the medical academic research conducted in Sweden and offers the countryÂ´s broadest range of education in medicine and health sciences. Since 1901 the Nobel Assembly at Karolinska Institutet selects the Nobel laureates in Physiology or Medicine.
Alex Heeley - De Facto Communications
14 Apr 10
Parents of babies and young children suffering from conditions such as asthma and eczema will be relieved to know there is a breakthrough product available that can drastically reduce their childâ€™s misery and symptoms.
13 Apr 10
The NGP union, held in the Netherlands last week saw over 50 visionaries gathered for the Supreme Court verdict against Myriad Genetics given on March 29th. They voted against their patent claims and a storm is brewing in the biotech community. The Court ruled that the patents should have never been granted because genes are a law of nature. With the majority of industry outsiders in agreement, how will the pharmaceutical world react?
13 Apr 10
Since the moment of the NHSâ€™s very inception in 1948, complementary medicine has formed an accepted and often-used element of the countryâ€™s national health service. Thousands of Brits swear blind by the efficacy of homeopathic treatments and rates of patient satisfaction are often far higher at the countryâ€™s homeopathic hospitals than they are on standard NHS wards. Yet while many patients claim a strong appreciation of the benefits of homeopathy, the science tells another story.
09 Apr 10
Until recently, pharmaceutical companies paid little attention to the process of maximising their data through publications. Today, several pharma firm and even consumer companies are beginning to recognise publications planning as an integral part of the marketing matrix. It now forms part of the overall communications strategy, adopted not only to raise awareness of a product and its key messages, but also to provide an evidence base for all other communication activities for the product.
Dr Sabah Al-Lawati
07 Apr 10
We often use them to make decisions about what products we buy and which we keep buyingâ€¦except for pharmaâ€™. Yet more than that, he makes a coherent and convincing argument for how these kinds of services could ultimately end up benefiting the pharma industry itself. Indeed while information from a single person on the internet might be far too subjective to be of use, the sophistication of the crowd is arguably much greater.
17 Feb 10
Research and development is the bread and butter of healthcare innovation. For decades the worldâ€™s pharmaceutical companies have treasured and protected this simple maxim, pouring billions of dollars into research and development and creating hundreds of groundbreaking new drugs in the process. Yet since the onset of the global financial crisis in 2007, big pharma has begun to ask some very difficult questions of its research commitments.
10 Feb 10
Diabetes mellitus â€“ more commonly known as just diabetes â€“ is a chronic metabolic condition that occurs as a result of either the pancreasâ€™ failure to produce normal insulin levels, or as a result of the bodyâ€™s inability to make use of the insulin that it does produce.